Given the current paucity of effective therapeutics for KRAS mutation-positive NSCLC, these observations support the evaluation of L-NAME or perhaps other NOS inhibitors for the treatment of this disease. The gene discussed is NOS2; the disease is non-small cell lung carcinoma.